Comparison of 24-hour glycemic excursions in patients with type 2 diabetes receiving additional anti-diabetic agents, acarbose versus sitagliptin, by using continuous glucose monitoring (CGM).

Trial Profile

Comparison of 24-hour glycemic excursions in patients with type 2 diabetes receiving additional anti-diabetic agents, acarbose versus sitagliptin, by using continuous glucose monitoring (CGM).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2016

At a glance

  • Drugs Acarbose (Primary) ; Sitagliptin (Primary) ; Antihypercalcaemics
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2011 Actual end date is 1 May 2011 University Hospital Medical Information Network - Japan.
    • 18 Jun 2011 Status changed from recruiting to completed according to University Hospital Medical Information Network - Japan.
    • 25 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top